Posted by Michael Wonder on 15 Jun 2020
COVID-19 and remdesivir: rethinking how we measure a drug’s ‘value’
15 June 2020 - As pharmaceutical and biotech companies scramble to identify treatments for COVID-19, a new disease that initially had none, we must begin to figure out what is an appropriate pricing approach — and price — for emerging therapies.
Remdesivir, Gilead Sciences’ repurposed anti-viral drug, offers the first opportunity to do this.
The Institute for Clinical and Economic Review has conducted the first value assessment of remdesivir, a drug with early evidence of treatment effectiveness. Its analysis, however, is premature and highlights many of the flaws inherent in today’s value assessment models.
